Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Primary Target

Transient receptor potential cation channel subfamily M member 5

6

Histamine H1 receptor

315

Dopamine D2 receptor

297

DNA

278

Bacterial penicillin-binding protein

233

All Match

Any Match

Exclude Selected

Exclude Selected

Development Status

US Previously Marketed

5

Other

1

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

5

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1960

5

Unknown

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Allergic disease

5

Hepatitis C

5

Unknown

1

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

5

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

5

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Kaken Pharmaceutical

5

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

6

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

6

EPA CompTox

6

FDA UNII

6

PUBCHEM

6

ECHA (EC/EINECS)

5

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

4

Principal Form

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 6 of 6 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

TRIPHENYLPHOSPHINE OXIDE

Z69161FKI3

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Transient receptor potential cation channel subfamily M member 5

Conditions:

Triphenylphosphine oxide (TPPO) is a neurotoxic very stable polar compound present in waste organic solutions from the chemical and pharmaceutical industry. The acute toxicity of TPPO LC50=12.2µg/mL, LC90=29.5µg/mL is higher than triphenyltin acetat...

e so that a correct management in the relationship with sustainable chemistry is strongly required. TPPO was identified as a selective and potent inhibitor of transient receptor potential melastatin-5 (TRPM5), but at the same moment, it had no effect (up to 100 μM) on the membrane potential responses of TRPA1, TRPV1, or TRPM4b.

CLEMIZOLE

T97CB3796L

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1960

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Hepatitis C virus

Transient receptor potential cation channel subfamily M member 5

Histamine H1 receptor

Conditions:

Allergic disease

Clemizole is a drug in clinical development for the treatment of hepatitis C virus (HCV) infection. Clemizole is a novel inhibitor of TRPC5 channels. Clemizole is an H1 antagonist. Clemizole, an antihistamine drug that was once widely used for treatm...

ent of allergic disease, was recently discovered to be a potent inhibitor (IC50, 24 nM) of the interaction between an HCV protein (NS4B) and HCV RNA. Although clemizole was widely used during the 1950s and 1960s, this was before contemporary regulatory requirements were established for new drug development, and there is very minimal information about its pharmacokinetics and metabolism.

CLEMIZOLE UNDECYLATE

6K5XAP3A37

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1960

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Hepatitis C virus

Transient receptor potential cation channel subfamily M member 5

Histamine H1 receptor

Conditions:

Allergic disease

Clemizole is a drug in clinical development for the treatment of hepatitis C virus (HCV) infection. Clemizole is a novel inhibitor of TRPC5 channels. Clemizole is an H1 antagonist. Clemizole, an antihistamine drug that was once widely used for treatm...

ent of allergic disease, was recently discovered to be a potent inhibitor (IC50, 24 nM) of the interaction between an HCV protein (NS4B) and HCV RNA. Although clemizole was widely used during the 1950s and 1960s, this was before contemporary regulatory requirements were established for new drug development, and there is very minimal information about its pharmacokinetics and metabolism.

CLEMIZOLE PENICILLIN

5UL276H6TF

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1960

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Hepatitis C virus

Transient receptor potential cation channel subfamily M member 5

Histamine H1 receptor

Conditions:

Allergic disease

Clemizole is a drug in clinical development for the treatment of hepatitis C virus (HCV) infection. Clemizole is a novel inhibitor of TRPC5 channels. Clemizole is an H1 antagonist. Clemizole, an antihistamine drug that was once widely used for treatm...

ent of allergic disease, was recently discovered to be a potent inhibitor (IC50, 24 nM) of the interaction between an HCV protein (NS4B) and HCV RNA. Although clemizole was widely used during the 1950s and 1960s, this was before contemporary regulatory requirements were established for new drug development, and there is very minimal information about its pharmacokinetics and metabolism.

CLEMIZOLE SULFATE

5AA1G805H0

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1960

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Hepatitis C virus

Transient receptor potential cation channel subfamily M member 5

Histamine H1 receptor

Conditions:

Allergic disease

Clemizole is a drug in clinical development for the treatment of hepatitis C virus (HCV) infection. Clemizole is a novel inhibitor of TRPC5 channels. Clemizole is an H1 antagonist. Clemizole, an antihistamine drug that was once widely used for treatm...

ent of allergic disease, was recently discovered to be a potent inhibitor (IC50, 24 nM) of the interaction between an HCV protein (NS4B) and HCV RNA. Although clemizole was widely used during the 1950s and 1960s, this was before contemporary regulatory requirements were established for new drug development, and there is very minimal information about its pharmacokinetics and metabolism.

CLEMIZOLE HYDROCHLORIDE

85W6I13D8M

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1960

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Hepatitis C virus

Transient receptor potential cation channel subfamily M member 5

Histamine H1 receptor

Conditions:

Allergic disease

Clemizole is a drug in clinical development for the treatment of hepatitis C virus (HCV) infection. Clemizole is a novel inhibitor of TRPC5 channels. Clemizole is an H1 antagonist. Clemizole, an antihistamine drug that was once widely used for treatm...

ent of allergic disease, was recently discovered to be a potent inhibitor (IC50, 24 nM) of the interaction between an HCV protein (NS4B) and HCV RNA. Although clemizole was widely used during the 1950s and 1960s, this was before contemporary regulatory requirements were established for new drug development, and there is very minimal information about its pharmacokinetics and metabolism.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1